By vgreene, 27 May, 2020 Observational multinational registry analysis; 671 hospitals on 6 continents; 96,032 hospitalized pts (mean age 53y) w/ confirmed COVID-19 treated w/ CQ (n=1,868), CQ + macrolide (n=3,783), HCQ (n=3,016), HCQ + macrolide (n=6,221) w/in 48h of dx, or no tx
By vgreene, 27 May, 2020 Hydroxychloroquine or Chloroquine With or Without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis
By vgreene, 27 May, 2020 Study considerations: retrospective registry study; propensity score matching analysis to minimize confounders but unmeasured variables still possible; dosing and duration only provided in aggregate, dose-response analysis not done; QT intervals not measu
By vgreene, 27 May, 2020 Adjusted analysis for in-hospital mortality (overall 11.1%), CQ 16.4%, CQ + macrolide 22.2%, HCQ 18%, HCQ + macrolide 23.8%, no tx 9.3%; rate of de novo ventricular arrhythmias CQ 4.3%, CQ + macrolide 6.5%, HCQ 6.1%, HCQ + macrolide 8.1%, no tx 0.3%; all
By switaschek, 27 May, 2020 Restore sinus rhythm1 via DC cardioversion, antiarrhythmic drug, or RF cath ablation; +/- rate control. No long-term anticoagulant tx (unless HCM).2 Correct underlying causes.
By vgreene, 27 May, 2020 Observational multinational registry analysis; 671 hospitals on 6 continents; 96,032 hospitalized pts (mean age 53y) w/ confirmed COVID-19 treated w/ CQ (n=1,868), CQ + macrolide (n=3,783), HCQ (n=3,016), HCQ + macrolide (n=6,221) w/in 48h of dx, or no tx